Research Focus

Research and Technology Management; Program Manager, Human Research Protections Operations

Recent additions – View all

1. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction

   Journal Article

   Morris, P. G.; Dickler, M.; Mcarthur, H. L.; Traina, T.; Sugarman, S.; Lin, N.; Moy, B.; Come, S.; Godfrey, L.; Nulsen, B.; more...
   Journal of Clinical Oncology (2009)

   Fulltext@MSK | Save
2. A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study

   Meeting Abstract

   Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Geneus, S.; Godfrey, L.; Norton, L.; Hudis, C.
   Cancer Research (2009)

   Fulltext@MSK | Save
3. Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: No evidence of short-term changes in left ventricular ejection fraction

   Meeting Abstract

   Morris, P. G.; Dickler, M.; Mcarthur, H.; Traina, T.; Godfrey, L.; Steingart, R.; Rugo, H.; Lin, N.; Moy, B.; Come, S.; more...
   Cancer Research (2009)

   Fulltext@MSK | Save